Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?

School of Chemistry and Manchester Interdisciplinary Biocentre, University of Manchester, 131 Princess Street, Manchester M1 7DN, UK.
dressNature Reviews Drug Discovery (Impact Factor: 37.23). 04/2008; 7(3):205-20. DOI: 10.1038/nrd2438
Source: PubMed

ABSTRACT It is generally thought that many drug molecules are transported across biological membranes via passive diffusion at a rate related to their lipophilicity. However, the types of biophysical forces involved in the interaction of drugs with lipid membranes are no different from those involved in their interaction with proteins, and so arguments based on lipophilicity could also be applied to drug uptake by membrane transporters or carriers. In this article, we discuss the evidence supporting the idea that rather than being an exception, carrier-mediated and active uptake of drugs may be more common than is usually assumed - including a summary of specific cases in which drugs are known to be taken up into cells via defined carriers - and consider the implications for drug discovery and development.

  • Toxicology Letters 09/2014; 229:S140. DOI:10.1016/j.toxlet.2014.06.494 · 3.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We exploit the recent availability of a community reconstruction of the human metabolic network (‘Recon2’) to study how close in structural terms are marketed drugs to the nearest known metabolite(s) that Recon2 contains. While other encodings using different kinds of chemical fingerprints give greater differences, we find using the 166 Public MDL Molecular Access (MACCS) keys that 90 % of marketed drugs have a Tanimoto similarity of more than 0.5 to the (structurally) ‘nearest’ human metabolite. This suggests a ‘rule of 0.5’ mnemonic for assessing the metabolite-like properties that characterise successful, marketed drugs. Multiobjective clustering leads to a similar conclusion, while artificial (synthetic) structures are seen to be less human-metabolite-like. This ‘rule of 0.5’ may have considerable predictive value in chemical biology and drug discovery, and may represent a powerful filter for decision making processes. Electronic supplementary material The online version of this article (doi:10.1007/s11306-014-0733-z) contains supplementary material, which is available to authorized users.
    Metabolomics 04/2015; 11(2). DOI:10.1007/s11306-014-0745-8 · 3.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the second half of 2014 the Manchester Institute of Biotechnology, based in Manchester (UK), hosted the first SupraBiology congress, an event attended by representatives of different academic institutions and industry based in both the UK and China. The congress was aimed to serve as a platform to discuss and promote potential collaborations between the UK and China on the subject of Systems Biology and High Performance Computing. The event, sponsored by the " BBSRC China Partnering Awards " and ISBE, was organised as a sequence of talks addressing the different aspects of Systems Biology that can benefit from High Performance Computing. A general discussion session followed where the scientific, technical , and logistic aspects of the prospected UK-China collaborations were examined. In what follows we summarize the contributions of the different attendees to the congress. In particular, the material hereby presented is organized around five main areas of interest: Systems Biology in medicine Computational methods of Systems Biology Computational Biology for Industry Computational Systems Biology in Education Computational Biology on the Tianhe-2 Supercom-puter The report ends with a discussion section relating the ideas that have been pushed forward to establish collaborations between UK and China.


1 Download
Available from